NF 340: Selective P2Y11 Antagonist for Purinergic Signaling Research

Executive Summary: NF 340 (SKU: B7508) is a chemically defined, selective P2Y11 antagonist supplied by APExBIO. This compound inhibits the G protein-coupled P2Y11 receptor, a key modulator in purinergic signaling and immune response pathways (source: product_spec). Peer-reviewed evidence demonstrates that NF 340 reverses quinolinate phosphoribosyltransferase (QPRT)-induced breast cancer invasiveness by reducing myosin light chain phosphorylation (source: Liu et al., 2021). The product displays a molecular weight of 986.84 and is intended strictly for research purposes, not for therapeutic or diagnostic applications (source: product_spec). Optimal use requires fresh solution preparation and short-term application due to limited aqueous stability (source: product_spec).

Biological Rationale

The P2Y11 receptor is a G protein-coupled receptor (GPCR) that responds to extracellular nucleotides, mediating critical signaling in immune modulation, inflammation, and cancer biology (source: Liu et al., 2021). NF 340, also known by its IUPAC name sodium (Z)-N-(3,7-disulfonaphthalen-1-yl)-4-methyl-3-(((Z)-((2-methyl-5-((Z)-oxido((3-sulfo-7-sulfonatonaphthalen-1-yl)imino)methyl)phenyl)imino)oxidomethyl)amino)benzimidate, provides researchers with a highly selective tool to dissect this receptor's role in cell signaling and disease models (source: product_spec). The P2Y11 receptor has been implicated in the control of cytokine release, leukocyte activation, and the regulation of tumor cell migration and invasiveness, making antagonists such as NF 340 critical for mechanistic studies in immunology and oncology (source: Strategic Interventions in GPCR Signaling).

Mechanism of Action of NF 340

NF 340 functions as a competitive antagonist of the P2Y11 receptor. By binding to the receptor, it prevents activation by endogenous nucleotides such as ATP, thereby inhibiting downstream signaling events—including cAMP accumulation and activation of phospholipase C (source: product_spec). This suppression affects GPCR-mediated pathways that regulate immune cell activity, inflammatory responses, and cancer cell behavior. In breast cancer models, NF 340 was shown to reverse QPRT-induced invasiveness by reducing phosphorylation of the myosin light chain, suggesting a mechanistic link between purinergic signaling and cytoskeletal dynamics (source: Liu et al., 2021).

Evidence & Benchmarks

• NF 340 reverses QPRT-induced breast cancer cell invasiveness and myosin light chain phosphorylation in vitro (source: Liu et al., 2021).
• Product purity, chemical identity, and molecular weight (986.84 g/mol) are verified by APExBIO analytical data (source: product_spec).
• NF 340 exhibits solubility below 19.74 mg/ml in water at ambient temperature (source: product_spec).
• Inhibition of the P2Y11 receptor by NF 340 is selective, with minimal off-target effects reported in comparative GPCR signaling assays (source: P2Y11 Antagonist B7508: Modulating Cancer Invasiveness).
• Freshly prepared solutions are required for reliable results due to limited chemical stability (source: product_spec).

This article extends prior summaries—such as NF 340 (SKU B7508): Scenario-Driven Solutions for P2Y11 Antagonist Use—by providing detailed, evidence-based protocol parameters and explicit source citations for key numeric claims.

In contrast to P2Y11 Antagonist B7508: Unveiling Novel Pathways in Cancer, this article centers on quantitative, reproducible laboratory benchmarks rather than hypothesis-driven pathway speculation.

Applications, Limits & Misconceptions

NF 340 is employed primarily in research settings to dissect the function of the P2Y11 receptor in immune modulation, inflammation pathway studies, and cancer cell signaling. Studies confirm its utility in breast cancer invasion models, where it enables the decoupling of QPRT-driven cytoskeletal changes from purinergic receptor activity (source: Liu et al., 2021).

Common Pitfalls or Misconceptions

• NF 340 is not suitable for clinical, diagnostic, or therapeutic applications (source: product_spec).
• Long-term storage of prepared solutions leads to reduced efficacy due to solubility and stability limitations (source: product_spec).
• Off-target GPCR effects are minimal, but not fully absent at supra-physiological concentrations (source: P2Y11 Antagonist B7508).
• The compound does not inhibit other P2Y receptor subtypes with the same potency as P2Y11 (workflow_recommendation).
• Results from in vitro models may not directly translate to in vivo systems without further validation (workflow_recommendation).

Workflow Integration & Parameters

For optimal performance in laboratory workflows, strict attention to preparation and storage is required. APExBIO recommends storing NF 340 as a solid at -20°C and preparing fresh solutions immediately prior to use (source: product_spec).

Protocol Parameters

• assay: P2Y11 receptor antagonism | value_with_unit: 1–10 μM | applicability: in vitro cell signaling inhibition | rationale: Reproducible inhibition of cAMP and PLC signaling | source_type: peer_reviewed
• assay: Compound storage | value_with_unit: -20°C (solid) | applicability: long-term stability | rationale: Preserves chemical integrity | source_type: product_spec
• assay: Working solution stability | value_with_unit: <24 h at 4°C | applicability: short-term use | rationale: Prevents degradation and ensures potency | source_type: workflow_recommendation
• assay: Aqueous solubility | value_with_unit: <19.74 mg/ml in water | applicability: solution preparation | rationale: Prevents precipitation, ensures dosing accuracy | source_type: product_spec

Conclusion & Outlook

NF 340, as a selective P2Y11 antagonist, offers a precise tool for dissecting GPCR-mediated cell signaling in immunology and cancer models. Its utility in reversing QPRT-driven breast cancer invasiveness is supported by robust peer-reviewed data (source: Liu et al., 2021). The product’s stability and selectivity parameters are well-defined, though limitations in long-term solution use and in vivo translation remain. Future research will benefit from integrating NF 340 into advanced cellular and molecular assays, with strict adherence to preparation and storage protocols for consistent results (source: product_spec).